HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bigger Stage Expected For Durbin’s Supplement Industry Criticism

This article was originally published in The Tan Sheet

Executive Summary

One of Congress' most vocal critics of dietary supplements, Sen. Dick Durbin, likely will have greater clout under the Obama presidency, with increased regulation of supplements a likely personal priority

You may also be interested in...

Melatonin Snacks Prompt Durbin Questions On Dietary Ingredients in Food

Sen. Dick Durbin wants FDA to issue guidance clarifying the agency's authority to regulate foods containing dietary ingredients as additives.

FDA Enforcement Branches Out With Wilderness Family Lawsuit

A Minnesota business set up shell Web sites to continue to make unapproved drug claims for dietary supplements FDA had warned the company against, the agency says in a lawsuit

With Democrat In White House, “More Aggressive” FDA Comes Into Focus

Democratic control of the White House, Senate and House brings the potential of a "more aggressive" FDA into sharp focus

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts